161 related articles for article (PubMed ID: 10063206)
1. Topical tocoretinate improved hypertrophic scar, skin sclerosis in systemic sclerosis and morphea.
Mizutani H; Yoshida T; Nouchi N; Hamanaka H; Shimizu M
J Dermatol; 1999 Jan; 26(1):11-7. PubMed ID: 10063206
[TBL] [Abstract][Full Text] [Related]
2. Clinical effect of tocoretinate on lichen and macular amyloidosis.
Terao M; Nishida K; Murota H; Katayama I
J Dermatol; 2011 Feb; 38(2):179-84. PubMed ID: 21269316
[TBL] [Abstract][Full Text] [Related]
3. Palindromic morphea: multiple recurrence of morphea lesions in a case of systemic sclerosis.
Mizutani H; Tanaka H; Okada H; Mizutani T; Shimizu M
J Dermatol; 1992 May; 19(5):298-301. PubMed ID: 1644954
[TBL] [Abstract][Full Text] [Related]
4. [Systemic sclerosis (scleroderma) without scleroderma].
Nadashkevych ON
Lik Sprava; 2001; (3):93-4. PubMed ID: 11560041
[TBL] [Abstract][Full Text] [Related]
5. Retinoic acid for treatment of systemic sclerosis and morphea: A literature review.
Thomas RM; Worswick S; Aleshin M
Dermatol Ther; 2017 Mar; 30(2):. PubMed ID: 28032675
[TBL] [Abstract][Full Text] [Related]
6. Tocoretinate inhibited the contraction of collagen gel matrices by human dermal fibroblasts with tenascin-C expression.
Yamada E; Mizutani H; Yoshida T; Isoda K; Shimizu M
J Dermatol Sci; 1999 Dec; 22(1):45-53. PubMed ID: 10651229
[TBL] [Abstract][Full Text] [Related]
7. Nodular scleroderma: focally increased tenascin expression differing from that in the surrounding scleroderma skin.
Mizutani H; Taniguchi H; Sakakura T; Shimizu M
J Dermatol; 1995 Apr; 22(4):267-71. PubMed ID: 7541812
[TBL] [Abstract][Full Text] [Related]
8. Ichthyotic-appearing skin changes associated with childhood morphea, systemic sclerosis, and systemic lupus erythematosus/scleroderma overlap.
Williams CM; Storm CA; Burns C; Rigby W; Dinulos JG
Pediatr Dermatol; 2010; 27(2):170-3. PubMed ID: 20537069
[TBL] [Abstract][Full Text] [Related]
9. Generalized morphea: a case report.
Payapvipapong K; Aunhachoke K
J Med Assoc Thai; 2010 Nov; 93 Suppl 6():S215-7. PubMed ID: 21280538
[TBL] [Abstract][Full Text] [Related]
10. Imaging of collagen deposition disorders using optical coherence tomography.
Ring HC; Mogensen M; Hussain AA; Steadman N; Banzhaf C; Themstrup L; Jemec GB
J Eur Acad Dermatol Venereol; 2015 May; 29(5):890-8. PubMed ID: 25178655
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of scleroderma with PUVA therapy.
Kanekura T; Fukumaru S; Matsushita S; Terasaki K; Mizoguchi S; Kanzaki T
J Dermatol; 1996 Jul; 23(7):455-9. PubMed ID: 8772023
[TBL] [Abstract][Full Text] [Related]
12. Coexistence of morphea and systemic sclerosis.
Soma Y; Tamaki T; Kikuchi K; Abe M; Igarashi A; Takehara K; Ishibashi Y
Dermatology; 1993; 186(2):103-5. PubMed ID: 8428037
[TBL] [Abstract][Full Text] [Related]
13. [Morphological changes in the skin in scleroderma in the process of treatment with unithiol].
Dubinskiĭ AA; Tseraidis GS; Guĭda PP; Petrusenko EA; Babykina EA
Vrach Delo; 1978 Oct; (10):112-4. PubMed ID: 716343
[No Abstract] [Full Text] [Related]
14. Two cases of refractory discoid lupus erythematosus successfully treated with topical tocoretinate.
Terao M; Matsui S; Katayama I
Dermatol Online J; 2011 Apr; 17(4):15. PubMed ID: 21549090
[TBL] [Abstract][Full Text] [Related]
15. Fibronectin. Localization in normal human skin, granulation tissue, hypertrophic scar, mature scar, progressive systemic sclerotic skin, and other fibrosing dermatoses.
Nagata H; Ueki H; Moriguchi T
Arch Dermatol; 1985 Aug; 121(8):995-9. PubMed ID: 3896159
[TBL] [Abstract][Full Text] [Related]
16. [Effect of piascledine treatment of scleroderma].
Szczepański A; Dabrowska H; Moskalewska K
Przegl Dermatol; 1975; 62(4):555-8. PubMed ID: 1162105
[No Abstract] [Full Text] [Related]
17. [Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin].
Dziankowska-Bartkowiak B; Zebrowska A; Wagrowska-Danielewicz M; Kobos J; Waszczykowska E
Przegl Lek; 2009; 66(12):1040-5. PubMed ID: 20514902
[TBL] [Abstract][Full Text] [Related]
18. Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma.
Hulshof MM; Bouwes Bavinck JN; Bergman W; Masclee AA; Heickendorff L; Breedveld FC; Dijkmans BA
J Am Acad Dermatol; 2000 Dec; 43(6):1017-23. PubMed ID: 11100017
[TBL] [Abstract][Full Text] [Related]
19. Localized and systemic scleroderma show different histological responses to methotrexate therapy.
Seyger MM; van den Hoogen FH; van Vlijmen-Willems IM; van de Kerkhof PC; de Jong EM
J Pathol; 2001 Apr; 193(4):511-6. PubMed ID: 11276011
[TBL] [Abstract][Full Text] [Related]
20. Extracorporeal photochemotherapy in systemic sclerosis and severe morphea.
Cribier B; Faradji T; Le Coz C; Oberling F; Grosshans E
Dermatology; 1995; 191(1):25-31. PubMed ID: 8589478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
